• Capstone Therapeutics retired about 85% of its original $6.82 million convertible note principal through conversions, cutting the remaining balance to $1 million.
• The July 2025 convertible note has been fully retired; only the October 2025 note remains outstanding.
• Outstanding convertible note principal fell from $1.9 million as of June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-031423), on September 29, 2026, and is solely responsible for the information contained therein.